Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29277674 | 0.91 | NCF1 (0.43) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL16633283 | 0.88 | NCF1 (0.50) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL29956251 | 0.86 | MAPT (0.52) | NCF1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL20346 | 0.86 | MAPT (0.52) | NCF1MAPTKDM4EMEN1ALDH1A1 | |
| Isoquinoline SCHEMBL28837903 | 0.84 | CYP1A2 (0.40) | NCF1LOXL2MAPTKDM4ELMNA | |
| SCHEMBL27841441 | 0.80 | NPC1 (0.40) | NCF1MAPTKDM4EADRB2ALDH1A1 | |
| SCHEMBL29952534 | 0.76 | KDM4C (0.41) | KDM4EALDH1A1HTT | |
| SCHEMBL16010409 | 0.76 | NCF1 (0.37) | NCF1LOXL2HTR1AADRA1DADRA1A | |
| SCHEMBL17540994 | 0.75 | HSP90AA1 (0.39) | HTR1AMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL13740419 | 0.75 | NCOA1 (0.41) | MAPTKDM4EMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249685-A | Ortho-diaryl substituted phenanthrene or phenanthroline carrier transport material and preparation method and application thereof | 华南理工大学 | 2022-03-29 | — | — | CN | claimed |
| EP-2176277-B1 | NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF | UNIV GEORGIA STATE RES FOUND (US) | 2016-02-24 | — | — | EP | claimed |
| US-9096856-B2 | Nucleotides and aptamers containing boronic acid groups having biased binding to glycosylated proteins, and uses thereof | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2015-08-04 | — | — | US | claimed |
| US-20130184160-A1 | NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | claimed |
| US-20110144187-A1 | APTAMER INHIBITION OF THROMBUS FORMATION | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION | 2011-06-16 | — | — | US | claimed |
| EP-2310054-A2 | APTAMER INHIBITION OF THROMBUS FORMATION | Georgia State University Research Foundation, Inc. (US) | 2011-04-20 | — | — | EP | claimed |
| EP-2176277-A2 | NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF | Georgia State University Research Foundation, Inc. (US) | 2010-04-21 | — | — | EP | claimed |
| WO-2010019847-A2 | APTAMER INHIBITION OF THROMBUS FORMATION | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2010-02-18 | — | — | WO | claimed |
| WO-2009012363-A2 | NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| EP-4703357-A1 | TRIAZOLYL-CONTAINING COMPOUNDS | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20250188053-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | REATA PHARMACEUTICALS, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2006125621-A1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-0773248-B1 | Polymers with heterocyclic side groups | MISSISSIPPI POLYMER TECHNOLOGI (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-0773248-A1 | Polymers with heterocyclic side groups | MAXDEM INCORPORATED (US) | 1997-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184160-A1 | NUCLEOTIDES AND APTAMERS CONTAINING BORONIC ACID GROUPS HAVING BIASED BINDING TO GLYCOSYLATED PROTEINS, AND USES THEREOF | TENT4A, PABPC4, NUDT21 | NCF1 2006/4885LOXL2 4701/4885HTR1A 4059/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | NCF1 348/4885LOXL2 3139/4885HTR1A 4819/4885 |
| US-20110144187-A1 | APTAMER INHIBITION OF THROMBUS FORMATION | FGB, F13B, GP6 | NCF1 1585/4885LOXL2 3924/4885HTR1A 4792/4885 |
| US-20250188053-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | RORC, RORB, RORA | NCF1 828/4885LOXL2 3331/4885HTR1A 4188/4885 |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | NCF1 1174/4885LOXL2 3142/4885HTR1A 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.